ERBB2 and breast cancer: Numerous studies support the close relationship between HER2 positivity and trastuzumab responsiveness (20, 22) and bearing in mind that a HER2-amplification rate of approximately 25% occurs in breast cancer, initial clinical trials may not have yielded significant data had no pre-selection of patients according to HER2 status taken place (23).